Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnesium orotate in heart failure with reduced ejection fraction
DRKS00014829Phase 2Completed
- Sponsor
- Wörwag Pharma
- Start
- Jul 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of magnesium orotate in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Wörwag Pharma. Primary endpoint: NT-proBNP change. Started Jul 2018; status: completed.
02
Drugs
magnesium orotate
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on DRKS00014829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00014829.